Recipients of Experimental Herpes Vaccine File Lawsuit

The suit claims that Rational Vaccines, the company of recently deceased researcher William Halford, violated US and international laws when it carried out the procedure.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, BERNARDASVThree people who developed adverse side effects after receiving injections of an unapproved, experimental herpes vaccine have taken the matter to court, according to a lawsuit filed on Friday (March 9) in Illinois (via Kaiser Health News). Southern Illinois University researcher William Halford, who was responsible for the creation of the vaccine and the injections themselves, died last summer, but the recipients of his vaccine are claiming compensation from his company, Rational Vaccines, which they claim violated US and international laws that protect the rights of study participants.

“My clients are anxious to ensure such unethical experimentation on human subjects are not repeated,” Alan Milstein, a New Jersey lawyer who is representing the three participants, tells Kaiser Health News. The suit requests compensation for both the costs of medical care and for the “pain and suffering” and loss of dignity incurred by the participants.

Two of the procedures mentioned in the suit were carried out in 2016 as part of an unsanctioned trial in the Caribbean island nation St. Kitts and Nevis that included testing on 20 people. “The Ministry of Health states categorically that neither the Cabinet, the Ministry of Health, the office of Chief Medical Officer nor the St. Kitts and Nevis Medical Board has ever been approached on this project,” ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies